Novel poly(ethylene glycol) derivatives for preparation of ribosome-inactivating protein conjugates

被引:16
作者
Arpicco, S
Dosio, F
Bolognesi, A
Lubelli, C
Brusa, P
Stella, B
Ceruti, M
Cattel, L
机构
[1] Dipartimento Sci & Tecnol Farm, I-10125 Turin, Italy
[2] Dipartimento Patol Sperimentale, I-40126 Bologna, Italy
[3] Dipartimento Farmacochim Tossicol & Biol, I-90123 Palermo, Italy
关键词
D O I
10.1021/bc015578s
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
This study describes the synthesis, characterization, and reactivity of new methoxypoly(ethylene glycol) (mPEG) derivatives containing a thioimidoester reactive group. These activated polymers are able to react with the lysyl c-amino groups of suitable proteins, generating an amidinated linkage and thereby preserving the protein's positive charge. mPEG derivatives of molecular weight 2000 and 5000 Da were used, and two spacer arms were prepared, introducing chains of different lengths between the hydroxyl group of the polymer and the thioimidate group. These mPEG derivatives were used to modify gelonin, a cytotoxic single-chain glycoprotein widely used in preparation of antitumoral conjugates, whose biological activity is strongly influenced by charge modification. The reactivity of mPEG thioimidates toward lysil epsilon-amino groups of gelonin was evaluated, and the results showed an increased degree of derivatization in proportion to the molar excesses of the polymer used and to the length of the alkyl spacer. Further studies showed that the thioimidate reactive is able to maintain gelonin's significant biological activity and immunogenicity. On the contrary, modification of the protein with N-hydroxysuccinimide derivative of mPEG strongly reduces the protein's cytotoxic activity. Evaluation of the pharmacokinetic behavior of native and PEG-grafted gelonin showed a marked increase in plasma half-life after protein PEGylation; in particular, the circulating life of the conjugates increased with increased molecular weight of the polymer used. The biodistribution test showed lower organ uptake after PEGylation, in particular by the liver and spleen.
引用
收藏
页码:757 / 765
页数:9
相关论文
共 58 条
[1]  
ALLEN EH, 1962, J BIOL CHEM, V237, P760
[2]   New coupling reagents for the preparation of disulfide cross-linked conjugates with increased stability [J].
Arpicco, S ;
Dosio, F ;
Brusa, P ;
Crosasso, P ;
Cattel, L .
BIOCONJUGATE CHEMISTRY, 1997, 8 (03) :327-337
[3]   Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells [J].
Atkinson, SF ;
Bettinger, T ;
Seymour, LW ;
Behr, JP ;
Ward, CM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (30) :27930-27935
[4]   The plant ribosome inactivating proteins luffin and saporin are potent inhibitors of HIV-1 integrase [J].
Au, TK ;
Collins, RA ;
Lam, TL ;
Ng, TB ;
Fong, WP ;
Wan, DCC .
FEBS LETTERS, 2000, 471 (2-3) :169-172
[5]   LARGE-SCALE CHROMATOGRAPHIC PURIFICATION OF RIBOSOME-INACTIVATING PROTEINS [J].
BARBIERI, L ;
STOPPA, C ;
BOLOGNESI, A .
JOURNAL OF CHROMATOGRAPHY, 1987, 408 :235-243
[6]   Polynucleotide:adenosine glycosidase activity of ribosome-inactivating proteins: Effect on DNA, RNA and poly(A) [J].
Barbieri, L ;
Valbonesi, P ;
Bonora, E ;
Gorini, P ;
Bolognesi, A ;
Stirpe, F .
NUCLEIC ACIDS RESEARCH, 1997, 25 (03) :518-522
[7]   BLOOD CLEARANCE AND ORGAN DISTRIBUTION AND TISSUE CONCENTRATION OF NATIVE, HOMOPOLYMERIZED AND IGG-CONJUGATED RIBOSOME-INACTIVATING PROTEINS [J].
BARBIERI, L ;
BATTELLI, MG ;
STIRPE, F .
XENOBIOTICA, 1990, 20 (12) :1331-1341
[8]   In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins [J].
Bolognesi, A ;
Polito, L ;
Tazzari, PL ;
Lemoli, RM ;
Lubelli, C ;
Fogli, M ;
Boon, L ;
De Boer, M ;
Stirpe, F .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 110 (02) :351-361
[9]   FORMATION OF NON-AMIDINE PRODUCTS IN REACTION OF PRIMARY AMINES WITH IMIDO ESTERS [J].
BROWNE, DT ;
KENT, SBH .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1975, 67 (01) :126-132
[10]   A PHASE-II STUDY OF EFFECT OF ADDITION OF TRICHOSANTHIN TO ZIDOVUDINE IN PATIENTS WITH HIV DISEASE AND FAILING ANTIRETROVIRAL AGENTS [J].
BYERS, VS ;
LEVIN, AS ;
MALVINO, A ;
WAITES, L ;
ROBINS, RA ;
BALDWIN, RW .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (04) :413-420